Quarterly ResultApr 28, 2026, 07:56 AM
WVE Q1 Revenue +316% to $38.2M; Net Loss $(26.1)M; Regains WVE-006 Rights
AI Summary
Wave Life Sciences Ltd. reported a significant increase in Q1 2026 revenue to $38.2 million, up from $9.2 million in Q1 2025, and a reduced net loss of $(26.1) million compared to $(46.9) million year-over-year. The company also announced plans for a Redomiciliation to become a Delaware corporation, subject to shareholder and court approvals. Additionally, Wave regained full rights to its WVE-006 program from GSK and GSK selected a fourth program to advance under their collaboration.
Key Highlights
- Q1 2026 revenue increased to $38.2M from $9.2M in Q1 2025 (+316%).
- Q1 2026 net loss reduced to $(26.1)M from $(46.9)M in Q1 2025.
- Regained full rights to WVE-006 program from GSK on February 2, 2026.
- GSK selected a fourth program to advance, with $32.0M in initiation payments.
- Cash and cash equivalents were $544.6M as of March 31, 2026.
- Expects existing cash to fund operations for at least the next 12 months.
- Announced Redomiciliation to a Delaware corporation on April 15, 2026.